OOIR: Observatory of International Research

Papers

(The TQCC of Movement Disorders is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Issue Information	431
	139
John Michael Walshe (April 24, 1920–October 14, 2022)	113
Severe Dyskinesia After Administration of SARS‐CoV2 mRNA Vaccine in Parkinson's Disease	111
Has Parkinson Disease Gone to the Dogs?	104
In Situ Global Structural Proteome Analysis Identifies Potential Biomarkers for Parkinson's Disease	104
FARS‐ADL across Ataxias: Construct Validity, Sensitivity to Change, and Minimal Important Change	91
Clinical and Molecular Spectrum of Autosomal Recessive CA8‐Related Cerebellar Ataxia	87
	85
The Pathogenesis of Paroxysmal Kinesigenic Dyskinesia: Current Concepts	85
	82
Complex Ataxia‐Dementia Phenotype in Patients with Digenic TBP/STUB1 Spinocerebellar Ataxia	82
Issue Information	80
DBSMatchMaker: Connecting Clinicians Globally for Deep Brain Stimulation in Rare Diseases	77
Movement Disorders: Volume 39, Number 4, April 2024	75
	73
Blocking the Self‐Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition	68
An Exploratory, Randomized, Double‐Blind Clinical Trial of Dipraglurant for Blepharospasm	67
Reply to: “Is Gait Dysfunction Prominent Sign of Isolated Rapid Eye Movement Sleep Behavior Disorder?”	67
Negative Myoclonus: Neurophysiological Study and Clinical Impact in Progressive Myoclonus Ataxia	67
Unraveling the Twist: Spatial Navigational Challenges in Cervical Dystonia	66
Covid‐19 Infection and Parkinsonism: Is There a Link?	65
Mortality of People with Parkinson's Disease in a Large UK‐Based Cohort Study: Time Trends and Relationship to Disease Duration	62
Confirmation of a Causal Role for SHQ1 Variants in Early Infantile‐Onset Recessive Dystonia	61
Response to Mortimer et al. “Clinical and molecular profiling in GNAO1 permits phenotype–genotype correlation”	61

Responsive Deep Brain Stimulation: A New Hope for Controlling Stimulation‐Induced Dysarthria in Essential Tremor	59
Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease	58
Canine RNF170 Single Base Deletion in a Naturally Occurring Model for Human Neuroaxonal Dystrophy	57
	57
Long‐Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early‐Onset Parkinson's Disease	56
Prokineticin‐2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients	56
Severe Acute Motor Exacerbations (SAME) across Metabolic, Developmental and Genetic Disorders	56
Epidemiology of Huntington's Disease in Latin America: A Systematic Review and Meta‐Analysis	56
Functional Movement Disorder as a Prodromal Symptom of Parkinson's Disease—Clinical and Pathophysiological Insights	55
September Infographic	55
Reply to: “CAG Repeat Expansion in THAP11 is Not Detected in a Cohort with Spinocerebellar Ataxia from Hokkaido, the Northernmost Island of Japan”	54
A New Case Series Suggests That SCA48 (ATX/STUB1) Is Primarily a Monogenic Disorder	54
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study	53
Clinical and Molecular Profiling in GNAO1 Permits Phenotype–Genotype Correlation	53
November Infographic	53
Dual Task Turning in Place: A Reliable, Valid, and Responsive Outcome Measure of Freezing of Gait	52
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure	52
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers	51
Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors	50
Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension	48
ANO3 as a Cause of Early‐Onset Chorea Combined with Dystonia: Illustration of Phenotypic Evolution	48
Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease	47
Reply to Letter to the Editor: “Disease Progression in Multiple System Atrophy: The Value of Clinical Cohorts with Long Follow‐Up”	46
Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease	45
Reply to: Comment on “Summing MDS‐UPDRS Parts 1 + 2 (Non‐motor and Motor Experience of Daily Living): The Patient's Voice”	45
Reply to: “Is Conscientiousness Related to the Risk of Parkinson's Disease?”	44
Reply to ‘Comment on Martino et al. ‘Scales for Antipsychotic‐Associated Movement Disorders: Systematic Review, Critique, and Recommendations’”	44
Issue Information	44
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study	44
Corticospinal Suppression Underlying Intact Movement Preparation Fades in Parkinson's Disease	42
HbA1c and Motor Outcome in Parkinson's Disease in the Mark‐PD Study	42
Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder	42
The Genetic Drivers of Juvenile, Young, and Early‐Onset Parkinson's Disease in India	42
Editor's Note	41
Movement Disorders: Volume 38, Number 3, March 2023	41
Movement Disorders: Volume 37, Number 7, July 2022	41
July Infographic	41
	40
Reply to: “The First Allogeneic Hematopoietic Stem Cell Transplantation in a Polish Patient with Adult‐Onset Leukoencephalopathy with Spheroids and Pigmented Glia”	40
Education, Other Topics	40
Keyword index	40
Movement Disorders: Volume 36, Number 5, May 2021	40
Movement Disorders: Volume 37, Number 12, December 2022	40
Cost‐Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease	39
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early	39
Movement Disorders: Volume 36, Number 7, July 2021	39
Evaluation of SORL1 in Lewy Body Dementia Identifies No Significant Associations	39
Movement Disorders: Volume 36, Number 12, December 2021	38
	38
The Ratio of Expanded to Normal Ataxin 3 in Peripheral Blood Mononuclear Cells Correlates with the Age at Onset in Spinocerebellar Ataxia Type 3	38

Reply to: Comparing VUS and AUS: Parallels and Differences in Neurogenetics and Neuroimmunology	38
Harnessing Transcriptomics to Decipher Dystonia Pathogenesis	37
Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected	36
Reply to: “Parkinson's Disease, Premature Mortality, and Amygdala”	36
Eye‐of‐Tiger Sign in Globus Pallidus: A Novel Radiological Feature of Spinocerebellar Ataxia Type 28	36
Risk Disclosure in Prodromal Parkinson's Disease	36
Neuropathology of McLeod Syndrome	35
Sensitivity of Sniffer Dogs for a Diagnosis of Parkinson's Disease: A Diagnostic Accuracy Study	35
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?	35
Reply to: “Age‐Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK‐PD)”	34
Acute Hemichorea‐Hemiballismus Following COVID‐19 (AZD1222) Vaccination	34
Reply to: “Overlapping Ranges in Levels Indicate That Hexosylsphingosine Is Not a Clinically Relevant Biomarker for GBA1‐Associated Parkinson's Disease”	34
Movement Disorders: Volume 37, Number 2, February 2022	34
Patients' Perspective of Dystonia Symptoms during the SARS‐CoV‐2 Pandemic	34
Efficacy of Caffeine in ADCY5‐Related Dyskinesia: A Retrospective Study	33
Abstracts	33
	33
Motor Features in a Peruvian Cohort of Parkinson's Disease Patients	32
Device‐Assisted and Neuromodulatory Therapies for Parkinson's Disease: A Network Meta‐Analysis	32
Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa‐Foscarbidopa Hydrate: Histopathology	32
Reply to: “HbA1c and Motor Outcome in Parkinson's Disease in the Mark‐PD Study”	32
Mild Motor Signs in Healthy Aging Are Associated with Lower Synaptic Density in the Brain	32
Impact of COVID‐19 on Patient Care, Training, and Research in Movement Disorders in MDS‐AOS Region	31
Multimodal Longitudinal Neurophysiological Investigations in Dopa‐Responsive Dystonia	31
Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease	30
Lateralized Effect of Thalamic Deep Brain Stimulation Location on Verbal Abstraction	30
Issue Information	30
Cognition and Psychiatric Disturbances	30
A TNR Frameshift Variant in Weimaraner Dogs with an Exercise‐Induced Paroxysmal Movement Disorder	30
Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R‐Related Leukoencephalopathy	30
Stressing the Importance of Cholinergic Interneurons in Striatal Function	29
Issue Information	29
A Critical Investigation of Cerebellar Associative Learning in Isolated Dystonia	29
Genetics and Metabolic Diseases	29
The South African Parkinson's Disease Study Collection	29
Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease	28
Reply to: Juvenile PLA2G6‐parkinsonism due to Indian ‘Asian’ p.R741Q mutation, and response to STN DBS	28
Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders	28
Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease	28
Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk	28
Differences Among Native Hawaiian, Asian, and White Patients with Progressive Supranuclear Palsy	27
Issue Information	27
Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease	27
Fostering Voice Objective Analysis in Patients with Movement Disorders	27
Issue Information	27
RFC1‐Related Disorder: In Vivo Evaluation of Spinal Cord Damage	27
Ca²⁺–Calmodulin–Calcineurin Signaling Modulates α‐Synuclein Transmission	27
October Infographic	27
Unraveling the Missing Heritability in Late‐Onset Cerebellar Ataxia	27
	26
Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives	26
Long‐Term Globus Pallidus Internus Deep Brain Stimulation in Pediatric Non‐Degenerative Dystonia: A Cohort Study and a Meta‐Analysis	26
	26
Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder	26
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism	26
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy	26
α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property	25
Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression	25
YY1: A New Gene for Childhood Onset Dystonia with Prominent Oromandibular‐Laryngeal Involvement?	25
Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta‐Analysis	25
Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes	25
Neuron‐Derived Misfolded α‐Synuclein in Blood: A Potential Biomarker for Parkinson's Disease?	25
Epidemiology and Rating Scales	24
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism	24
(TTTCA)exp Drives the Genotype–Phenotype Correlation and Genetic Anticipation in FCMTE1	24
Issue Information	24
High Praise for Domen and Colleagues	24
Movement Disorders: Volume 38, Number 7, July 2023	24
Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds	24
It Takes Guts: A Novel Model for Gut‐to‐Brain Propagation of Alpha‐Synuclein and Tau	24
Social Cognition in Parkinson's Disease after Focused Ultrasound Subthalamotomy: A Controlled Study	23
Role of Bβ1 overexpression in the pathogenesis of SCA12	23
Movement Disorders: Volume 40, Number 2, February 2025	23
Metagenomic Analysis Reveals Large‐Scale Disruptions of the Gut Microbiome in Parkinson's Disease	23
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia	23
Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD)	23
Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record	23
HOMER‐3 Antibodies Were Not Detected in Two German Cohorts of Patients with Multiple System Atrophy	23
Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts	23
Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design	22

Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology‐Proven Cases	22
Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease	22
Welcoming 2025 and a New Editorial Term	22
Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy–Richardson Syndrome	22
Thalamic Deep Brain Stimulation Versus Magnetic Resonance–Guided Focused Ultrasound in Tremor Patients: A Retrospective Single‐Surgeon Comparison	22
Identification of Novel Genetic Loci Affecting Age at Onset of Parkinson's Disease: A Genome‐wide Association Study	22
Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis	22
Microstructural Abnormalities of the Dentatorubrothalamic Tract in Cervical Dystonia	22
X‐Linked Dystonia‐Parkinsonism (“Lubag”) May Present with Peripheral Synucleinopathy	22
Strong Correlation between Clinical Improvement and Low‐Frequency Oscillations in Pediatric Dystonia	22
The Effect of Dysautonomia on Motor, Behavioral, and Cognitive Fluctuations in Parkinson's Disease	22
Cerebellar Transcranial Direct Current Stimulation in the Cerebellar Cognitive Affective Syndrome: A Randomized, Double‐Blind, Sham‐Controlled Trial	22
A Unified Framework for Evidence‐Based Diagnostic Criteria Programs in Movement Disorders	21
Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction	21
Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach	21
Early Changes in Striatal Activity and Motor Kinematics in a Huntington's Disease Mouse Model	21
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials	21
Altered Medial Prefrontal Connectivity in Parkinson's Disease Patients with Somatic Symptoms	21
Stratification Tools for Disease‐Modifying Trials in Prodromal Synucleinopathy	21
Evaluation of a Structured Screening Assessment to Detect Isolated Rapid Eye Movement Sleep Behavior Disorder	21
Long‐Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease	21
Measuring Tremor—A Comparison of Automated Video Analysis, Neurophysiology, and Clinical Rating	21
Dry‐Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation	20
Subclinical Epileptiform Activity in Dementia with Lewy Bodies	20
Preparing for Disease‐Modification Trials in Degenerative Cerebellar Ataxias: Which Endpoints to Choose?	20
A Multi‐center Genome‐wide Association Study of Cervical Dystonia	20
More Than Just the Level of Consciousness: Comparing Asleep and Awake Deep Brain Stimulation	20
Translational Pharmacology of PRAX‐944, a Novel T‐Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor	20
Identification of a DAGLB Mutation in a Non‐Chinese Patient with Parkinson's Disease	20
Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short‐Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease	19
	19
Dysregulated Cerebrospinal Fluid Proteome of Spinocerebellar Ataxia Type 2 and its Clinical Implications	19
Magnetic Resonance Imaging–Guided Focused Ultrasound Thalamotomy in Spinocerebellar Ataxia Type 12	19
A Novel Variant of ATP5MC3 Associated with Both Dystonia and Spastic Paraplegia	19
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study	19
Editor's Note	19
In Memoriam Mahlon R. DeLong (1938–2024)	19
Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics	19
Diagnostic Criteria for Primary Tic Disorders: Time for Reappraisal	19
Gamified Closed‐Loop Intervention Enhances Tic Suppression in Children: A Randomized Trial	19
Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease	19
α‐Synuclein Seed Amplification Assays from Blood‐Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the Evidence	19
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia	19
Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease	18
A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design	18
A Pilot Group Cognitive Behavioral Therapy Telehealth Intervention for Functional Movement Disorder	18
Sodium Oxybate in Alcohol‐Responsive Essential Tremor of Voice: An Open‐Label Phase II Study	18
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial	18
Reply to: “THAP11 CAG Expansion Beyond Chinese‐Ancestry Cohorts: An Examination of 1000 Genomes and UK Biobank”	18
	18
Development and Validation of the Dystonia‐Pain Classification System: A Multicenter Study	18
Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy	18
Immunometabolic Signature and Tauopathy Markers in Blood Cells of Progressive Supranuclear Palsy	18
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease	18
Astrocyte Responses Influence Local Effects of Whole‐Brain Magnetic Stimulation in Parkinsonian Rats	17
Resting‐State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease‐Mild Cognitive Impairment	17
Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease	17
Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia	17
Gain‐of‐Function KIDINS220 Variants Disrupt Neuronal Development and Cause Cerebral Palsy	17
The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait—A Randomized Motion Sensor Study	17
Diagnostic Value of Salivary Real‐Time Quaking‐Induced Conversion in Parkinson's Disease and Multiple System Atrophy	17
Neuroticism and Risk of Parkinson's Disease: A Meta‐Analysis	17
Is Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome?	17
Intermediate and Expanded HTT Alleles and the Risk for α‐Synucleinopathies	17
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease	17
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12	17
Long‐Term Follow‐Up of Pediatric Patients with Dyskinetic Cerebral Palsy and Deep Brain Stimulation	17
Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans	17
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease	17
Interpersonal Psychotherapy for the Treatment of Depression in Parkinson's Disease: Results of a Randomized Controlled Trial	17
Sensitivity to Change and Patient‐Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data‐Driven Analysis	16
Cerebrospinal FluidBiomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders	16
The Impact of Type 2 Diabetes in Parkinson's Disease	16
Genetic Testing in Parkinson's Disease	16
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway	16
Plasma Glutathione and Prodromal Parkinson's Disease Probability	16
Variable Age at Onset in AOPEP‐Associated Dystonia	16
Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease	16
Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta‐Analysis	16
Neuromelanin‐Sensitive Magnetic Resonance Imaging Changes in the Locus Coeruleus/Subcoeruleus Complex in Patients with Typical and Atypical Parkinsonism	16
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers	16
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study	16
Magnetic Resonance–Guided Focused Ultrasound Thalamotomy May Spare Dopaminergic Therapy in Early‐Stage Tremor‐Dominant Parkinson's Disease: A Pilot Study	16
Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson's Disease Using Gait Parameters	16
Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial	16
Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants	16
Does Cognitive Impairment Influence Motor Speech Performance in De Novo Parkinson's Disease?	16
Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease	15
Increased Free Water in the Substantia Nigra in Asymptomatic LRRK2 G2019S Mutation Carriers	15
An MDS Evidence‐Based Review on Treatments for Huntington's Disease	15
Comparison of Transcranial Sonography and [¹⁸F]‐Fluorodopa PET Imaging in GBA1 Mutation Carriers	15
Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease	15
Plasma Biomarkers and Disease Prognosis in Mild Cognitive Impairment with Lewy Bodies	15
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations	15
	15